Zacks Small Cap has inched its third-quarter 2025 earnings forecast for Longeveron Inc. higher, trimming the biotech’s expected loss to 26 cents a share. The research note, issued Aug. 14 by analyst B. Sorensen, offers a modest but notable vote of confidence in the Nasdaq-listed company.

Zacks Research analysts have reduced their earnings per share estimate for KeyCorp in fiscal year 2027 to $1.71. The report, released on July 1st, reflects an updated outlook for the financial services provider.